Get the Stockscreener App
4.47
0.90%
0.04
Scisparc Ltd stock is traded at $4.47, with a volume of 4,816.
It is up +0.90% in the last 24 hours and down -9.70% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$4.43
Open:
$4.4719
24h Volume:
4,816
Relative Volume:
0.43
Market Cap:
$2.60M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0193
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
-5.30%
1M Performance:
-9.70%
6M Performance:
+46.08%
1Y Performance:
-89.04%
1-Day Range:
$4.29
$4.60
1-Week Range:
$4.20
$4.70
52-Week Range:
$2.98
$43.65
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
4.47 | 2.60M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scisparc Ltd Stock (SPRC) Latest News
Net loss narrows to $6.05M, but SciSparc (SPRC) raises substantial doubt about continuing operations. - Stock Titan
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome - OTC Markets
SciSparc Awarded Three Patents For Its Novel Compounds and Methods - OTC Markets
Scisparc Ltd (SPRC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial - TipRanks
Tourette drug cut tics 21% in study as SciSparc (SPRC) advances trials - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - The Manila Times
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - marketscreener.com
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - The Manila Times
26 children have joined SciSparc’s two-compound autism treatment trial - Stock Titan
Neurothera Labs Inc. Announces Share Consolidation - TradingView
Neurothera Labs Inc. Announces Share Consolidation - FinancialContent
Neurothera Labs Inc. Announces Share Consolidation - TheNewswire
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com South Africa
SciSparc appoints AI professor to advisory board - Investing.com
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com Canada
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com India
Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026 - marketscreener.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionIV Crush Alert - vinanet.vn
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com Canada
SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind - Stock Titan
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com India
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com UK
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionCommon Gap - careplusvn.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionSpring Pattern - dars.gov.et
FDA Guidance Includes MDMA as a Psychedelic Drug; SciSparc Patent Application Published - Stock Titan
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com Canada
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - Yahoo Finance
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TradingView
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZoneRevenue Growth Stocks - dars.gov.et
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - Yahoo Finance
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scisparc Ltd Stock (SPRC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shrem Itschak | Director |
Jun 01 '26 |
Sale |
10.00 |
462 |
4,620 |
10,596 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):